Antibacterial, Anti-Biofilm and Antibiotic-Potentiating Activity of Extracts from Five Edible and Medicinal Macrofungi against Multidrug-Resistant Clinical Pathogens
DOI:
https://doi.org/10.70882/e5wzkw09Keywords:
Antibiotic Adjuvant, Antimicrobial Resistance, Biofilm, Macrofungi, Selectivity Index.Abstract
Antimicrobial resistance is among the leading global health threats. Macrofungi are
an unexploited reservoir of secondary metabolites, yet their potential as adjuvants
against multidrug-resistant (MDR) pathogens remains little tested. This study aims
to extract bioactive fractions from five edible and medicinal macrofungi, quantify
their phytochemical content, evaluate their activity against five antibiotic-resistant
clinical phenotypes, and assess synergy with conventional antibiotics, biofilm
inhibition and cytotoxicity. Fruiting bodies of Ganoderma lucidum, Lentinula edodes,
Pleurotus ostreatus, Trametes versicolor and Auricularia polytricha were extracted
sequentially with n-hexane, ethyl acetate, ethanol and water. Phenolic, flavonoid and
polysaccharide contents were measured spectrophotometrically. Agar-well diffusion,
CLSI M07 broth microdilution, time–kill kinetics, checkerboard synergy, crystal-
violet biofilm assays, GC–MS dereplication and MTT cytotoxicity on Vero cells were
performed against MRSA, VRE, ESBL-producing Escherichia coli, carbapenem-
resistant Klebsiella pneumoniae (CRKP) and MDR Pseudomonas aeruginosa. The ethyl
acetate fraction of G. lucidum (GL-EA) and the ethanol fraction of T. versicolor (TV-
EtOH) were the most active, with MICs of 62.5–250 µg mL⁻¹ and MBC/MIC ratios
of 2 where determined. GL-EA was synergistic with oxacillin against MRSA (ΣFICI ≤
0.16) and with colistin against CRKP (0.25). Biofilm biomass fell by 45–66 % at ½ MIC.
Fourteen constituents were putatively annotated, dominated by linoleic acid,
ergosterol and oleic acid. Vero-cell IC₅₀ values were 383–618 µg mL⁻¹, giving
selectivity indices of 3.0–9.9. Extracts of G. lucidum and T. versicolor combine
bactericidal, anti-biofilm and antibiotic-potentiating activity against MDR pathogens
at selectivity acceptable for crude preparations. Bioassay-guided fractionation,
structural confirmation and in vivo validation are needed.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Pure and Applied Sciences (Science Forum)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


